Bicycle Therapeutics (BCYC) Non-Current Debt (2020 - 2024)
Bicycle Therapeutics' (BCYC) quarterly Non-Current Debt came in at $8.5 million in Q2 2024, down 72.13% YoY from $30.5 million in Q3 2023, and down 72.39% on a QoQ basis from $30.8 million in Q1 2024.
Bicycle Therapeutics (BCYC) Non-Current Debt (2020 - 2024) Analysis & Trends
Bicycle Therapeutics (BCYC) has 5 years of Non-Current Debt data on file, last reported at $8.5 million in Q2 2024.
- Quarterly Non-Current Debt fell 72.13% year-over-year to $8.5 million in Q2 2024, while the trailing twelve-month figure through Jun 2024 was $8.5 million (down 72.13% YoY) and the FY2023 annual result came in at $30.7 million, up 1.26% from the prior year.
- Non-Current Debt eased to $8.5 million in Q2 2024, from $30.8 million in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $30.8 million in Q1 2024 to a low of $8.5 million in Q2 2024.
- A 5-year average of $26.9 million and a median of $30.1 million in 2022 frame the typical range for Non-Current Debt.
- Annual changes were most pronounced in 2021 — Non-Current Debt soared 106.23% — and 2024, when it tumbled 72.13%.
- Tracing BCYC's Non-Current Debt over 5 years: stood at $14.5 million in 2020, then jumped by 105.95% to $29.9 million in 2021, then climbed by 1.48% to $30.3 million in 2022, then gained by 1.26% to $30.7 million in 2023, then plunged by 72.29% to $8.5 million in 2024.
- The last three Non-Current Debt figures came in at $8.5 million (Q2 2024), $30.8 million (Q1 2024), and $30.7 million (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Bicycle Therapeutics | 272.28 Mn | 272.28 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 8.51 Mn |
| Mar 31, 2024 | 30.80 Mn |
| Dec 31, 2023 | 30.70 Mn |
| Sep 30, 2023 | 30.60 Mn |
| Jun 30, 2023 | 30.51 Mn |
| Mar 31, 2023 | 30.42 Mn |
| Dec 31, 2022 | 30.32 Mn |
| Sep 30, 2022 | 30.23 Mn |
| Jun 30, 2022 | 30.14 Mn |
| Mar 31, 2022 | 30.01 Mn |
| Dec 31, 2021 | 29.87 Mn |
| Sep 30, 2021 | 29.75 Mn |
| Jun 30, 2021 | 29.63 Mn |
| Mar 31, 2021 | 29.50 Mn |
| Dec 31, 2020 | 14.51 Mn |
| Sep 30, 2020 | 14.43 Mn |